RU2015148055A - Полиплексы - Google Patents
Полиплексы Download PDFInfo
- Publication number
- RU2015148055A RU2015148055A RU2015148055A RU2015148055A RU2015148055A RU 2015148055 A RU2015148055 A RU 2015148055A RU 2015148055 A RU2015148055 A RU 2015148055A RU 2015148055 A RU2015148055 A RU 2015148055A RU 2015148055 A RU2015148055 A RU 2015148055A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- predetermined
- active agent
- paragraphs
- polymer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims 15
- 239000013543 active substance Substances 0.000 claims 14
- 229920000642 polymer Polymers 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229920002939 poly(N,N-dimethylacrylamides) Polymers 0.000 claims 2
- -1 (C 1 -C 6 ) -alkyl methacrylic acid Chemical compound 0.000 claims 1
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 claims 1
- HEBDGRTWECSNNT-UHFFFAOYSA-N 2-methylidenepentanoic acid Chemical compound CCCC(=C)C(O)=O HEBDGRTWECSNNT-UHFFFAOYSA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- OKPYIWASQZGASP-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361811078P | 2013-04-11 | 2013-04-11 | |
| US61/811,078 | 2013-04-11 | ||
| PCT/US2014/033873 WO2014169256A2 (en) | 2013-04-11 | 2014-04-11 | Polyplexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015148055A true RU2015148055A (ru) | 2017-05-16 |
Family
ID=51690135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015148055A RU2015148055A (ru) | 2013-04-11 | 2014-04-11 | Полиплексы |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10835549B2 (enExample) |
| EP (1) | EP2991616A4 (enExample) |
| JP (1) | JP2016518358A (enExample) |
| KR (1) | KR20150143639A (enExample) |
| CN (1) | CN105431134A (enExample) |
| AU (1) | AU2014250830A1 (enExample) |
| BR (1) | BR112015025968A2 (enExample) |
| CA (1) | CA2911315A1 (enExample) |
| HK (1) | HK1216152A1 (enExample) |
| MX (1) | MX2015014354A (enExample) |
| RU (1) | RU2015148055A (enExample) |
| WO (1) | WO2014169256A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3242886A4 (en) | 2015-01-08 | 2018-08-29 | Moerae Matrix, Inc., | Formulation of mk2 inhibitor peptides |
| CN104815333B (zh) * | 2015-04-05 | 2017-10-31 | 北京工业大学 | 一种聚离子胶束纳米粒子的制备方法及其应用 |
| US11147827B2 (en) | 2016-08-05 | 2021-10-19 | Vanderbilt University | Conjugation of lipophilic albumin-binding moiety to RNA for improved carrier-free in vivo pharmacokinetics and gene silencing |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004535388A (ja) * | 2001-04-30 | 2004-11-25 | ターゲティッド ジェネティクス コーポレイション | 脂質含有薬物送達複合体およびそれらの生成方法 |
| WO2003070823A2 (en) * | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| CA2513072A1 (en) * | 2003-01-09 | 2004-07-29 | Invitrogen Corporation | Cellular delivery and activation polypeptide-nucleic acid complexes |
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| JP5703466B2 (ja) * | 2007-08-07 | 2015-04-22 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | キナーゼ阻害薬およびその使用 |
| US9271933B2 (en) * | 2007-11-27 | 2016-03-01 | Rutgers, The State University Of New Jersey | Graft copolymer polyelectrolyte complexes for drug delivery |
| US20110060123A1 (en) * | 2008-04-30 | 2011-03-10 | Kazunori Kataoka | Charge conversional ternary polyplex |
| US20100150952A1 (en) * | 2008-11-07 | 2010-06-17 | University Of Washington | pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY |
| CA2744104C (en) * | 2008-12-10 | 2017-07-18 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US20130115256A1 (en) * | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
| CN115957297A (zh) | 2013-03-15 | 2023-04-14 | 节奏制药公司 | 药物组合物 |
-
2014
- 2014-04-11 AU AU2014250830A patent/AU2014250830A1/en not_active Abandoned
- 2014-04-11 MX MX2015014354A patent/MX2015014354A/es unknown
- 2014-04-11 CA CA2911315A patent/CA2911315A1/en not_active Abandoned
- 2014-04-11 EP EP14783124.2A patent/EP2991616A4/en not_active Withdrawn
- 2014-04-11 RU RU2015148055A patent/RU2015148055A/ru not_active Application Discontinuation
- 2014-04-11 JP JP2016507694A patent/JP2016518358A/ja active Pending
- 2014-04-11 CN CN201480033617.1A patent/CN105431134A/zh active Pending
- 2014-04-11 BR BR112015025968A patent/BR112015025968A2/pt not_active Application Discontinuation
- 2014-04-11 KR KR1020157032241A patent/KR20150143639A/ko not_active Withdrawn
- 2014-04-11 US US14/784,017 patent/US10835549B2/en active Active
- 2014-04-11 HK HK16104189.5A patent/HK1216152A1/zh unknown
- 2014-04-11 WO PCT/US2014/033873 patent/WO2014169256A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20160058876A1 (en) | 2016-03-03 |
| CA2911315A1 (en) | 2014-10-16 |
| EP2991616A2 (en) | 2016-03-09 |
| WO2014169256A2 (en) | 2014-10-16 |
| KR20150143639A (ko) | 2015-12-23 |
| BR112015025968A2 (pt) | 2018-01-09 |
| EP2991616A4 (en) | 2016-11-09 |
| AU2014250830A1 (en) | 2015-11-12 |
| HK1216152A1 (zh) | 2016-10-21 |
| US10835549B2 (en) | 2020-11-17 |
| JP2016518358A (ja) | 2016-06-23 |
| CN105431134A (zh) | 2016-03-23 |
| MX2015014354A (es) | 2016-06-07 |
| WO2014169256A3 (en) | 2014-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Faya et al. | Conjugates and nano-delivery of antimicrobial peptides for enhancing therapeutic activity | |
| US12447464B2 (en) | Polycationic microfibers and methods of using the same | |
| CY1108870T1 (el) | Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους | |
| RU2009121444A (ru) | Офтальмологические устройства и способы их изготовления и применения | |
| JP2018519835A5 (enExample) | ||
| JP2018502956A5 (enExample) | ||
| RU2015148055A (ru) | Полиплексы | |
| ATE474563T1 (de) | Hydrogelzusammensetzung zur transdermalen arzneistoffabgabe | |
| RU2015102027A (ru) | Проникающие в клетку пептиды и способы идентификации проникающих в клетку пептидов | |
| BR112021024463A2 (pt) | Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas | |
| WO2007069068A3 (en) | Cell penetrating peptide conjugates for delivering nucleic acids into cells | |
| ES2421916T3 (es) | Forma farmacéutica de sabor enmascarado que contiene roflumilast | |
| JP2015512938A5 (enExample) | ||
| WO2008154482A3 (en) | Sirna compositions and methods of use in treatment of ocular diseases | |
| JP2008531074A5 (enExample) | ||
| MX364396B (es) | Poli(beta-amino esteres) modificados para suministro de farmaco. | |
| JP2011522070A5 (enExample) | ||
| Li et al. | The application, neurotoxicity, and related mechanism of cationic polymers | |
| Jiang et al. | Complexation of DNA with cationic copolymer micelles: Effects of DNA length and topology | |
| JP2012199532A5 (enExample) | ||
| RU2016130448A (ru) | Пептидные дендримеры, содержащие фибриноген-связывающие пептиды | |
| JP2017513596A5 (enExample) | ||
| CL2009001077A1 (es) | Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo. | |
| JP2017528441A5 (enExample) | ||
| RU2010153904A (ru) | Ниацин-содержащие композиции с модифицированным высвобождением |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180704 |